FDA Aims to Shine Light on the Drug Approval Process
BY Nancy Scola | Tuesday, June 2 2009
The somewhat beleaguered Food and Drug Administration, reports the New York Times' Gardiner Harris, is setting up a "Transparency Task Force" to examine how the FDA can more fully open up its operations to the public -- particularly when it comes to the testing and approval process for new drugs. Harris notes that open government poses a unique set of challenges for the FDA, which must wrestle with managing high-value information on drug approvals and powerful pharmaceutical industry interests. (Harris's piece supplies some wonderful industry context for the move, and is well worth a read.)
According to the FDA website, the creation of the transparency task force is in direct response to President Obama's call for federal agencies to embrace more open and transparent government -- despite the fact that the White House has yet to issue a formal set of directives on the topic to the executive branch.